Concurrent chemoradiotherapy (CRT) is a common treatment modality for patients with advanced-stage head and neck cancer and results in high rates of locoregional disease control. Accurate assessment of disease response following completion of treatment is necessary to detect persistent disease and to direct surgical intervention if necessary. 18 F-fluorodeoxyglucose (FDG) positron-emission tomography (PET) or combined PET-computed tomography (CT) has become a valuable tool in the assessment of treatment response after chemoradiotherapy. While the precise timing of the scan remains controversial, the high negative predictive value of post-treatment PET-CT strongly suggests that a complete clinical response has been achieved. The functional imaging information provided by PET-CT can be combined with the structural imaging of contrastenhanced CT or magnetic resonance imaging (MRI) and physical examination to better predict those patients who would benefit from post-treatment surgical intervention.
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Chemoradiotherapy (CRT) has become a common treatment approach for patients with advanced head and neck cancer, particularly when the disease is unresectable or the loss of function from surgery is excessive.
Following such treatment, the majority of patients show a complete clinical response in the primary site. Some of these patients do not have a complete pathologic response, however, and their subclinical disease is difficult to confirm unless the patient subsequently undergoes surgery. The development of positron-emission tomography-computed tomography (PET-CT) imaging represents an important advance in helping the clinician to determine which patients are most likely to have persistent cancer following CRT. Such information is critical to providing the optimal chance for disease control as this relates both to the tumor in the primary site and the regional lymph nodes.
Radiologic Interpretation of Positron-emission Tomography-Computed Tomography After Chemoradiotherapy
Combined PET-CT examination of patients after CRT allows the integration of both anatomic and structural information with functional metabolic activity in the assessment of persistent disease. The timing of the assessment is controversial, as metabolic tracer uptake and activity can be appreciated for weeks to months after CRT. Persistent disease, inflammation, superimposed infection, and radionecrosis can all potentially contribute to residual tracer uptake (see Figure 1 ). Proper interpretation needs to account for such post-treatment changes and appropriately distinguish them from persistent disease.
In a recent review of published literature assessing the utility of PET and combined PET-CT for monitoring patients after CRT, focal tracer uptake was the parameter generally utilized to discriminate between persistent disease and post-treatment changes. 1 In general, focal asymmetric uptake within the primary site or lymph nodes, with intensity greater than the surrounding background and/or blood pool, should raise suspicion of potentially persistent disease. By contrast, post-treatment changes often appear non-focal and diffuse, conform to radiotherapy target volumes, and typically exhibit mild to moderate tracer uptake intensity. Likewise, new parameters such as total metabolic tumor volume and burden may provide additional prognostic information.
5-8

Prediction of Response to Chemoradiotherapy
An accurate and timely assessment of disease response after completion of CRT is critical for determining the need for surgical salvage versus clinical observation alone in patients with advanced head and neck cancer. As a result of better anatomic localization, combined PET-CT has fewer equivocal results and is more accurate than PET alone for the detection of head and neck cancer. 
Assessment of the Primary Tumor Site
A limited number of studies have examined the utility of PET-CT specifically for the assessment of tumor response at the primary tumor site after CRT. 3, 11, 12 There is substantial variability in the sensitivity and specificity of PET-CT for the detection of local disease based on these studies. The observed variations may be partially due to the time interval between completion of treatment and scanning. Similarly, a higher number of false-positive PET-CT scans are likely to be due to acute or chronic inflammation (see Figure 1 ). Inflammatory changes at the primary tumor site are typically related to recent treatment resulting in a relatively low positive predictive value (PPV) of PET-CT in detecting residual disease.
The negative predictive value (NPV) of PET-CT at the primary tumor site is of much greater utility for confirming disease response. In multiple studies, the NPV of PET-CT for primary tumor control has been shown to be >90 %. 3, 11, 12 A recent study on early (six-to eight-week)
post-treatment PET-CT in patients treated with intra-arterial CRT 
Assessment of Cervical Lymph Nodes
The utility of PET-CT imaging for the assessment of residual neck nodal disease after definitive CRT has been an area of intense study and debate. Historically, in patients presenting with clinically advanced nodal disease (N2 or N3), the conventional approach has been to perform a planned neck dissection after completion of CRT, regardless of the extent of disease response in the cervical nodes. [14] [15] [16] The rationale behind planned neck dissection in this group of patients was to remove any persistent nodal disease that could not be detected on physical examination or structural imaging studies and to confirm a complete pathological response.
Although still controversial, the treatment paradigm of routine planned neck dissection after CRT for patients with advanced nodal disease is beginning to change. Evidence from recent studies suggests that posttreatment neck dissection may not be necessary in patients with advanced neck disease achieving a complete clinical response after CRT based on physical examination and imaging studies that include the use of PET or PET-CT. Conversely, the real value of post-treatment PET-CT rests in its negative findings. In a meta-analysis by Isles et al. for PET alone, the pooled mean NPV for the detection of persistent or recurrent disease was 96%. 13 In individual studies utilizing PET-CT surveillance after CRT, the NPV ranged from 94 to 100% in predicting nodal response and corroborating the earlier data from PET alone. 3, 11, 20, 23 The high NPV of PET-CT for detection of persistent nodal disease after CRT is resulting in a significant change in patient management away from 
Timing of Positron-emission TomographyComputed Tomography and the Need for Surgical Intervention
The appropriate timing of PET-CT after CRT is also an area of ongoing investigation and debate. The optimal time interval between completion of CRT and PET-CT imaging should result in an accurate assessment of disease response in a timely manner. This will direct appropriate surgical intervention, if needed, or allow for conservative clinical observation.
PET-CT scans performed too early after treatment may produce a high rate of false-positive studies due to treatment-related inflammation.
Conversely, persistent disease below the level of detection for PET-CT may produce false-negative results if scanning is carried out too early.
A recent study performed by a multidisciplinary head and neck oncology team demonstrated an overall accuracy rate of only 60% at the primary site for PET-CT performed between six and eight weeks after the completion of CRT. 11 The NPV for the primary site as well as for the cervical nodes was, however, highly predictive of adequate The authors recommend an algorithm for patient management after CRT that comprises physical examination four to six weeks after completion of treatment to assess initial disease response, followed shortly thereafter by imaging with contrast-enhanced CT and PET-CT (see Figure 3 ). In order to prevent an unnecessary delay in identifying and treating residual disease, imaging should be performed no later than 12
weeks after the completion of treatment, with a preference towards earlier imaging (at eight weeks). Ultimately, clinicians must strive to achieve a balance between timely and accurate assessments of tumor response and preventing the risks associated with delaying the treatment of persistent disease. n
